Hiyam Abdelmagid, MD
Internal Medicine · Tallahassee, FLNPI 1174979157
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 632 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 632 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$925
- Lilly USA, LLC$912
- AstraZeneca$832
- Pfizer$830
- Bayer$788
- plus $5K from 33 others
What the payments were for
- Food & beverage$10,624100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 93 | $1,833 |
| AbbVie | 56 | $925 |
| Lilly USA, LLC | 74 | $912 |
| AstraZeneca | 44 | $832 |
| Pfizer | 43 | $830 |
| Bayer | 64 | $788 |
| Amgen | 36 | $575 |
| Abbott | 22 | $425 |
| Boehringer Ingelheim | 23 | $422 |
| Astellas Pharma US Inc | 24 | $391 |
| GSK | 18 | $280 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $239 |
| Sanofi-aventis U.S. LLC | 13 | $230 |
| Novartis | 12 | $210 |
| Merck | 12 | $177 |
| Biohaven Pharmaceuticals, Inc. | 9 | $148 |
| Exact Sciences | 7 | $122 |
| Almatica Pharma LLC | 7 | $120 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $115 |
| Johnson & Johnson | 6 | $115 |
| Idorsia Pharmaceuticals US Inc | 6 | $110 |
| Amarin Pharma, Inc. | 6 | $110 |
| Dexcom, Inc. | 6 | $108 |
| Corcept Therapeutics | 5 | $98 |
| Kowa Pharmaceuticals America, Inc. | 6 | $92 |
| UCB, Inc. | 3 | $89 |
| Phathom Pharmaceuticals, Inc. | 3 | $84 |
| IBSA Pharma Inc. | 2 | $34 |
| Medtronic | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 2 | $25 |
| Lundbeck LLC | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Biogen | 1 | $20 |
| Inogen, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$125
- Xultophy 100/3.6$124
- Wegovy$117
How this compares
$10,624 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 92 | $113,990 |
| OzempicSemaglutide | 74 | $84,622 |
| FarxigaDapagliflozin Propanediol | 72 | $82,727 |
| JardianceEmpagliflozin | 68 | $78,112 |
| JanuviaSitagliptin Phosphate | 54 | $59,078 |
| EliquisApixaban | 53 | $49,649 |
| KerendiaFinerenone | 35 | $37,448 |
| TrulicityDulaglutide | 29 | $28,935 |
| XareltoRivaroxaban | 18 | $27,401 |
| RybelsusSemaglutide | 16 | $26,549 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $21,440 |
| MyrbetriqMirabegron | 17 | $18,454 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $12,805 |
| DapagliflozinDapagliflozin Propanediol | 17 | $11,518 |
| TradjentaLinagliptin | 14 | $7,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $912 | $142,925121 claims |
| Novo NordiskOzempic, Rybelsus | $1,833 | $111,17190 claims |
| Boehringer IngelheimJardiance, Tradjenta | $422 | $85,34182 claims |
| AstraZenecaFarxiga | $832 | $82,72772 claims |
| MerckJanuvia, Janumet | $177 | $71,88469 claims |
| PfizerEliquis | $830 | $49,64953 claims |
| BayerKerendia | $788 | $37,44835 claims |
| Johnson & JohnsonXarelto | $115 | $27,40118 claims |
| GSKTrelegy Ellipta | $280 | $21,44020 claims |
| Astellas Pharma US IncMyrbetriq | $391 | $18,45417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Tallahassee
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.